Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Arvinder K, Dhalla"'
Autor:
Mir Hashim, Radhika Korupolu, Baber Syed, Kyle Horlen, Simret Beraki, Padma Karamchedu, Arvinder K. Dhalla, Rodolphe Ruffy, Mir Imran
Publikováno v:
Pharmacology Research & Perspectives, Vol 7, Iss 5, Pp n/a-n/a (2019)
Abstract Biotherapeutic agents must be administered parenterally to obtain therapeutic blood concentrations, lowering patient compliance and complicating care. An oral delivery platform (ODP) was developed to deliver drugs into the small intestinal w
Externí odkaz:
https://doaj.org/article/033713911bad42d1bf9fd27695db919f
Autor:
Alyson Yamaguchi, Jacques Van Dam, Arvinder K. Dhalla, Kyle Horlen, Mir Imran, April T. Vo, Mir A. Hashim
Publikováno v:
Frontiers in Drug Delivery. 2
Biotherapeutics such as peptides and antibodies are highly efficacious clinically but, unlike conventional medications, cannot be administered orally as they get digested and inactivated. Thus, biotherapeutics require parenteral routes for delivery,
Autor:
Laura Fusaro, Baber Syed, Shilpy Sharma, Radhika Korupolu, Anvesh Dasari, Betsy Gutierrez, Radia Abdul-Wahab, Padma Karamchedu, Mir Hashim, Delia Gratta, Shane Yen, April T Vo, Mir A. Imran, Anusha Garapaty, Simret Beraki, Asad Wasi, Mansoor Syed, Arvinder K. Dhalla, Kyle Horlen, Zachary Owyang, Alyson Yamaguchi, Chang Ong, Vasudha Salgotra, Leonard C Fung, Eric Liang, Ziad T. Al-Shamsie
Publikováno v:
Drug Delivery and Translational Research
Biotherapeutics are highly efficacious, but the pain and inconvenience of chronic injections lead to poor patient compliance and compromise effective disease management. Despite innumerable attempts, oral delivery of biotherapeutics remains unsuccess
Autor:
Radhika Korupolu, Mir A. Imran, Baber Syed, Mir Hashim, Simret Beraki, Kyle Horlen, Padma Karamchedu, Rodolphe Ruffy, Arvinder K. Dhalla
Publikováno v:
Pharmacology Research & Perspectives, Vol 7, Iss 5, Pp n/a-n/a (2019)
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives
Biotherapeutic agents must be administered parenterally to obtain therapeutic blood concentrations, lowering patient compliance and complicating care. An oral delivery platform (ODP) was developed to deliver drugs into the small intestinal wall. This
Autor:
Ziad T. Al-Shamsie, Padma Karamchedu, Anvesh Dasari, Arvinder K. Dhalla, Laura Fusaro, Delia Gratta, Eric Liang, Rodolphe Ruffy, Baber Syed, Anusha Garapaty, April Toledo, Radhika Korupolu, Mir Hashim, Shilpy Sharma, Leonard C Fung, Simret Beraki, Mir A. Imran, Radia Abdul Wahab, Alyson Yamaguchi, Vasudha Salgotra
Publikováno v:
Diabetes. 68
Aim: We developed a platform to painlessly deliver by mouth drugs that cannot be administered orally. This ingestible, capsule-like device deploys inside the small intestine and injects into its wall a biotherapeutic payload sealed inside a dissolvab
Autor:
Radhika Korupolu, Mir A. Imran, Padma Karamchedu, Baber Syed, Kyle Horlen, Simret Beraki, Arvinder K. Dhalla, Mir Hashim, Rodolphe Ruffy
Publikováno v:
Journal of the Endocrine Society
BACKGROUND: Biotherapeutic agents must be administered parenterally to reach and maintain therapeutic blood concentrations, lowering patient compliance and complicating long-term care. We have developed an ingestible robotic pill capable of deliverin
Autor:
Dmitry O, Koltun, Eric Q, Parkhill, Elfatih, Elzein, Tetsuya, Kobayashi, Gregory T, Notte, Rao, Kalla, Robert H, Jiang, Xiaofen, Li, Thao D, Perry, Belem, Avila, Wei-Qun, Wang, Catherine, Smith-Maxwell, Arvinder K, Dhalla, Sridharan, Rajamani, Brian, Stafford, Jennifer, Tang, Nevena, Mollova, Luiz, Belardinelli, Jeff A, Zablocki
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 26:3202-3206
We started with a medium throughput screen of heterocyclic compounds without basic amine groups to avoid hERG and β-blocker activity and identified [1,2,4]triazolo[4,3-a]pyridine as an early lead. Optimization of substituents for Late INa current in
Autor:
Arvinder K. Dhalla, Robert R. Henry, Patrick Yue, Pamela Wong, Jay S. Skyler, Philip Jochelson, Robert H. Eckel, Luiz Belardinelli
Publikováno v:
Diabetes Care
OBJECTIVE Ranolazine is an antianginal drug that mediates its effects by inhibition of cardiac late sodium current. Although ranolazine is not approved for the treatment of type 2 diabetes, in post hoc analyses of pivotal angina trials, ranolazine wa
Autor:
Kristopher M. Kahlig, Michael Krause, Ming Yang, Arvinder K. Dhalla, Sridharan Rajamani, Yun Ning, Luiz Belardinelli
Publikováno v:
Diabetes. 63:3545-3556
Pancreatic α-cells express voltage-gated Na+ channels (NaChs), which support the generation of electrical activity leading to an increase in intracellular calcium, and cause exocytosis of glucagon. Ranolazine, a NaCh blocker, is approved for treatme
Autor:
Jeff A, Zablocki, Elfatih, Elzein, Xiaofen, Li, Dmitry O, Koltun, Eric Q, Parkhill, Tetsuya, Kobayashi, Ruben, Martinez, Britton, Corkey, Haibo, Jiang, Thao, Perry, Rao, Kalla, Gregory T, Notte, Oliver, Saunders, Michael, Graupe, Yafan, Lu, Chandru, Venkataramani, Juan, Guerrero, Jason, Perry, Mark, Osier, Robert, Strickley, Gongxin, Liu, Wei-Qun, Wang, Lufei, Hu, Xiao-Jun, Li, Nesrine, El-Bizri, Ryoko, Hirakawa, Kris, Kahlig, Cheng, Xie, Cindy Hong, Li, Arvinder K, Dhalla, Sridharan, Rajamani, Nevena, Mollova, Daniel, Soohoo, Eve-Irene, Lepist, Bernard, Murray, Gerry, Rhodes, Luiz, Belardinelli, Manoj C, Desai
Publikováno v:
Journal of medicinal chemistry. 59(19)
Late sodium current (late I